Brookline Cap M Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to “Strong-Buy”

Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by equities research analysts at Brookline Cap M to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports. Brookline Cap M also issued estimates for Cardiol Therapeutics’ Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.29) EPS.

Several other analysts also recently weighed in on CRDL. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a research note on Monday, December 1st. Finally, Brookline Capital Acquisition raised Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Cardiol Therapeutics currently has a consensus rating of “Buy” and an average price target of $9.00.

Cardiol Therapeutics Stock Up 3.6%

Shares of CRDL traded up $0.03 during mid-day trading on Tuesday, reaching $0.99. 174,245 shares of the stock traded hands, compared to its average volume of 346,622. The stock has a fifty day simple moving average of $1.00 and a 200 day simple moving average of $1.09. Cardiol Therapeutics has a 12-month low of $0.77 and a 12-month high of $1.59. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.01. The firm has a market cap of $111.10 million, a price-to-earnings ratio of -3.32 and a beta of 1.04.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its earnings results on Thursday, November 13th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Sell-side analysts expect that Cardiol Therapeutics will post -0.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Cardiol Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its stake in Cardiol Therapeutics by 136.2% during the second quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock valued at $36,000 after purchasing an additional 15,255 shares during the last quarter. Thompson Davis & CO. Inc. acquired a new position in shares of Cardiol Therapeutics in the 2nd quarter valued at about $39,000. Boyer Financial Services Inc. bought a new stake in shares of Cardiol Therapeutics during the 4th quarter valued at about $33,000. Susquehanna International Group LLP raised its stake in Cardiol Therapeutics by 366.5% during the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after acquiring an additional 73,375 shares during the period. Finally, Sheets Smith Investment Management bought a new position in Cardiol Therapeutics in the third quarter worth about $152,000. 12.49% of the stock is currently owned by institutional investors.

Key Cardiol Therapeutics News

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CRDL to a “Strong‑Buy,” highlighting bullish analyst sentiment that can spur buying interest from investors and funds. Zacks Upgrade
• Positive Sentiment: Brookline published detailed EPS estimates for 2025–2026 (quarterly losses around $0.07–$0.08; FY2026 forecast ≈ ($0.29)), which are modestly less negative than the consensus FY2026 estimate of ($0.33). The slightly improved outlook vs. consensus can be read as a relative improvement in near‑term expectations. Brookline Estimates
• Neutral Sentiment: Published short‑interest data claims a “large increase” but simultaneously reports 0 shares short and NaN changes, with a days‑to‑cover of 0.0 — the figures look inconsistent and are unlikely to be a meaningful market driver until clarified by reliable data.
• Negative Sentiment: Brookline’s forecasts still show recurring quarterly losses and a negative FY outlook (company remains unprofitable). Ongoing losses limit valuation upside and mean the stock remains sensitive to funding, clinical, or regulatory news. Brookline Estimates

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.